Vivani Medical (NASDAQ:VANI) Stock: Insider Donald Dwyer Buys 20,000 Shares

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) insider Donald Dwyer bought 20,000 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were bought at an average price of $0.98 per share, with a total value of $19,600.00. Following the completion of the transaction, the insider directly owned 75,000 shares in the company, valued at approximately $73,500. This trade represents a 36.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vivani Medical Trading Up 2.7%

Shares of VANI stock traded up $0.03 on Friday, reaching $1.01. The company had a trading volume of 368,707 shares, compared to its average volume of 256,490. The stock has a market cap of $91.10 million, a PE ratio of -3.16 and a beta of 2.51. The company has a 50-day moving average of $1.18 and a 200-day moving average of $1.24. Vivani Medical, Inc. has a 12 month low of $0.80 and a 12 month high of $1.66.

Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its quarterly earnings results on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Wall Street Zen cut shares of Vivani Medical from a “hold” rating to a “sell” rating in a research report on Sunday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $3.75.

Get Our Latest Research Report on Vivani Medical

About Vivani Medical

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

Recommended Stories

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.